Hope for muscular dystrophy

Young boys with Duchenne muscular dystrophy (DMD), a progressive genetic disorder that causes muscles to weaken and eventually be replaced by scar tissue are being given a ray  of hope by Binhamton University, New York.

Muscular dystrophy (MD) is a group of genetic disorders that cause progressive muscle weakness and loss of muscle mass. 

Common types include:
Duchenne muscular dystrophy (DMD) – usually begins in early childhood and primarily affects boys.
Becker muscular dystrophy – similar to Duchenne but generally progresses more slowly.
Myotonic dystrophy – can cause muscle weakness, stiffness, and problems involving other organs.
Limb-girdle muscular dystrophy – mainly affects muscles around the hips and shoulders.
Facioscapulohumeral muscular dystrophy (FSHD) – often affects the face, shoulder blades, and upper arms.
Possible symptoms: difficulty running or climbing stairs, frequent falls, trouble getting up from the floor, progressive weakness, muscle wasting, and sometimes heart or breathing problems.
There is no single treatment for all muscular dystrophies. Depending on the type, treatment may include physiotherapy, medications, respiratory and cardiac care, mobility support, and genetic therapies.

There are several important new treatments for muscular dystrophy, especially for Duchenne muscular dystrophy (DMD). The field has moved beyond just treating symptoms.
Promising/current treatments
Gene therapy (Elevidys): A one-time treatment designed to deliver a shortened version of the dystrophin gene (“micro-dystrophin”) to muscle cells. In the U.S., it is approved for certain ambulatory patients age 4+ with DMD. UU.S. Food and Drug Administration+1
Givinostat (Duvyzat): A newer non-steroid medicine approved for DMD patients age 6+; it aims to reduce inflammation and muscle loss. UU.S. Food and Drug Administration
Exon-skipping drugs: Medicines such as eteplirsen, golodirsen, viltolarsen and casimersen can help certain genetic mutations produce a shorter but functional dystrophin protein. UU.S. Food and Drug Administration
Gene editing: Researchers are working on CRISPR-like approaches that could potentially correct the underlying mutation rather than simply compensate for it. These are still experimental. MMuscular Dystrophy Association.

New treatments for heart involvement: Cell-based treatments such as deramiocel are being evaluated for DMD-related cardiomyopathy, with FDA review activity in 2026. UU.S. Food and Drug Administration
There is real reason for hope, but gene therapy isn't a cure yet, and it has important eligibility and safety considerations. For example, the FDA added significant safety warnings and restrictions around Elevidys after reports of serious liver injury. 

This is certainly wonderful news - we wish the researchers all the best.

By Jamuna Rangachari